1 study found for:    18375893 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel and Sorafenib;   Drug: Paclitaxel

Indicates status has not been verified in more than two years